The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
The ETHICON 4000 Stapler and ETHICON 3D Reloads are now approved for use in both open and laparoscopic surgeries across the European Union
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Patients with BRCA mutations often face aggressive disease and poor prognosis
Subscribe To Our Newsletter & Stay Updated
